宇華(06169.HK)逆升7.6%重越牛熊線近15億人幣購山東英才學院九成權益
宇華教育(06169.HK)以近15億人民幣收購山東英才學院九成權益,該股今早逆市一舉升破5條移動平均線(250天線為3.54元),高開10%報3.63元欠承接,曾回順至3.35元,現造3.55元,續升7.6%,成交急增至2,336萬股,涉資8,115萬元。
宇華公布,附屬鄭州漢晨教育科技以14.92億元人民幣,收購持有民辦高等教育機構山東英才學院全部舉辦者權益之濟南雙勝教育諮詢90%股權。宇華聲明指,憑著今次收購,相信整合山東英才學院將大幅擴充及豐富公司的教育服務種類及地區分佈,提升本身於華北地區相對其他民辦教育供應商競爭優勢,以提高盈利潛力及長遠業務持續經營能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.